Bupropion-Memantine Combination in the Treatment of Major Depressive Disorder and Treatment-Resistant Depression - PubMed
4 hours ago
- #depression-treatment
- #pharmacotherapy
- #NMDA-antagonists
- Bupropion-dextromethorphan (BDC) is an FDA-approved oral combination targeting NMDA receptors and norepinephrine-dopamine systems, showing rapid antidepressant effects within the first week.
- BDC has limitations including contraindications in patients with eating disorders or seizure history, lack of efficacy for anxiety, and no cognitive improvement.
- Memantine is proposed as an alternative to BDC, offering treatment for both depression and cognitive impairments, and can be combined with bupropion or SSRIs/SNRIs.
- Fixed-dose combination pills like BDC are less flexible than separate prescriptions; BDC is limited to a specific dose ratio (105 mg bupropion/45 mg DXM).
- Cost analysis shows combinations involving memantine with SSRIs, SNRIs, or bupropion are significantly cheaper than BDC ($1,119 per month).
- The article suggests exploring bupropion-memantine or SSRI/SNRI-memantine combinations as cost-effective and flexible alternatives for treating MDD and TRD.